AC6.F ALZECURE PHARMA AB

Healthcare Pharmaceuticals Frankfurt Exchange
0.5620 EUR
Close of Nov 11, 2026
0.0830 0.7420
Market cap
EUR 64.6M
P/E
18.7x
P/B
7.52x
ROE
128.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is AC6.F undervalued?

Graham number
Price0.5620
Graham value0.2245
Premium150.3%

AC6.F trades 150.3% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

ALZECURE PHARMA AB fundamental analysis

No fundamental analysis for ALZECURE PHARMA AB yet.

ALZECURE PHARMA AB stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About ALZECURE PHARMA AB

AlzeCure Pharma AB (publ) operates as a pharmaceutical company that develops small-molecule drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is involved in the development of drug candidates based on the NeuroRestore, Alzstatin, and Painless research platforms. Its products pipeline includes ACD856 for the treatment of Alzheimer's disease, sleep disorders, depression, traumatic brain injuries, and Parkinso…

Full company profile